Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic Cancer

Annals of Surgical Oncology

Volumn 22, Issue , 2015, Pages 1574-1579

  Byers, Joshua T ^a   Paniccia, Alessandro ^a   Kaplan, Jeffrey ^b   Koenig, Michelle ^a   Kahn, Nate ^a   Wilson, Lora ^b   Chen, Lieping ^c   Schulick, Richard D ^a   Edil, Barish H ^a   Zhu, Yuwen ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 H5 PROTEIN; MEMBRANE PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; HHLA2 PROTEIN, HUMAN; IMMUNOGLOBULIN; TUMOR MARKER;

ACINAR CELL; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FROZEN SECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; NEUROENDOCRINE TUMOR; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS ISLET CELL; PANCREAS RESECTION; PROTEIN EXPRESSION; REVIEW; TUMOR ESCAPE; ADENOCARCINOMA; CANCER STAGING; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; METABOLISM; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; TUMOR CELL CULTURE;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULINS; NEOPLASM STAGING; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR CELLS, CULTURED;

EID: 84952873976     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4293-2     Document Type: Review

References (22)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586–94.
3. Cao H, Le D, Yang LX. Current status in chemotherapy for advanced pancreatic adenocarcinoma. Anticancer Res. 2013;33:1785–91.
4. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.
5. Sideras K, Braat H, Kwekkeboom J, van Eijck CH, Peppelenbosch MP, Sleijfer S, et al. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev. 2014;40:513–22.
6. Lunardi S, Muschel RJ, Brunner TB. The stromal compartments in pancreatic cancer: are there any therapeutic targets? Cancer Lett. 2014;343:147–55.
7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
8. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–48.
9. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–77.
10. Zhu Y, Yao S, Chen L. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity. 2011;34:466–78.
11. Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov. 2011;1:158–69.
12. Zhang Y, Zhang J, Xu K, Xiao Z, Sun J, Xu J, et al. PTEN/PI3 K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer. Hepatogastroenterology. 2013;60:1766–72.
13. Yi KH, Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev. 2009;229:145–51.
14. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151–7.
15. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–44.
16. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33.
17. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.
18. Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al. B7-H4, a molecule of the B7 family, negatively regulates T-cell immunity. Immunity. 2003;18:849–61.
19. Dangaj D, Scholler N. Blocking the B7-H4 pathway with novel recombinant antibodies enhances T-cell-mediated antitumor responses. Oncoimmunology. 2013;2:e25913.
20. Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R, et al. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res. 2013;73:4820–9.
21. Zhu Y, Yao S, Iliopoulou BP, Han X, Augustine MM, Xu H, et al. B7-H5 costimulates human T-cells via CD28H. Nat Commun. 2013;4:2043.
22. Wood LD. Pancreatic cancer genomes: toward molecular subtyping and novel approaches to diagnosis and therapy. Mol Diagn Ther. 2013;17:287–97.